 |
인쇄하기
취소
|
Albis takes on competitors’ brands
Daewoong Pharmaceutical is enjoying brisk sales of its new anti-ulcer drug, Albis.
Sales of Daewoong’s H2 receptor antagonist reached over 42 billion won last year, making it one of the top-selling drugs in the country.
Albis is a generic version of GlaxoSmithKline’s Zantac. Its market share has also gained momentum over the past four years, surpassing Ildong Pharm’s Curan and Boryung P...
Sales of Daewoong’s H2 receptor antagonist reached over 42 billion won last year, making it one of the top-selling drugs in the country.
Albis is a generic version of GlaxoSmithKline’s Zantac. Its market share has also gained momentum over the past four years, surpassing Ildong Pharm’s Curan and Boryung P...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.